Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy

por Ocasio-Rivera, Marinel, Marin-Maldonado, Frances, Trossi-Torres, Geraline, Ortiz-Rosado, Angely, Rodríguez-Irizarry, Valerie, Rodriguez-Lopez, Eric, Martínez, Sahayra, Almodóvar, Sharilyn, Suarez-Martínez, Edu
Publicado 2020